AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 30041587
Drug: Medications acknowledged
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medications acknowledged in PCP record
Trial: 21126127
Drug: Enoxaparin 40
RxNorm normalized name: ENOXAPARIN 40MG/0.4ML INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin 40 mg plus low dose aspirin (LDA), n = 30
Trial: 21126127
Drug: Enoxaparin 20
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin 20 mg plus LDA, n = 30
Trial: 7582386
Drug: Bezafibrate 400
RxNorm normalized name: bezafibrate 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bezafibrate 400 mg once a day
Trial: 16497101
Drug: Goeckerman's therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goeckerman's therapy (GT) including dermal application of crude coal tar and exposure to UV radiation
Trial: 17221216
Drug: Goeckerman's therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goeckerman's therapy (GT)
Trial: 14571257
Drug: Oral D-amphetamine
RxNorm normalized name: amphetamine / dextroamphetamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral D-amphetamine (AMPH) 30 mg
Trial: 9894373
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg sildenafil (adjustable to 100 mg or 25 mg based on efficacy and tolerability)
Trial: 22211208
Drug: Web-based intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Web-based intervention featuring actors simulating a patient discussing treatment concerns (N=24)
Trial: 22211208
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group shown an educational video about schizophrenia treatment (N=26)
Trial: 9381445
Drug: Letter arguing
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Letter arguing for reduction of daily benzodiazepine intake
Trial: 8410962
Drug: alprazolam (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alprazolam (1 mg) and alcohol (0.5 g/kg)
Trial: 8410962
Drug: alprazolam (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alprazolam (1 mg) and placebo drink
Trial: 8410962
Drug: placebo capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo capsule and alcohol (0.5 g/kg)
Trial: 8410962
Drug: placebo capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo capsule and placebo drink
Trial: 27864822
Drug: Home‐based hand‐arm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home‐based hand‐arm bimanual intensive therapy (H‐HABIT; n=12)
Trial: 19324530
Drug: oxcarbazepine (1,000‐2,400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oxcarbazepine (1,000‐2,400 mg/day)
Trial: 19324530
Drug: divalproex (750‐2,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: divalproex (750‐2,000 mg/day)
Trial: 17684201
Drug: DHA oil
RxNorm normalized name: Ulkenia DHA oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA oil (7.5 g DHA oil/d, equivalent to 3 g DHA/d)
Trial: 10088202
Drug: Ramipril 5
RxNorm normalized name: ramipril 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril 5 mg once a day for 4 weeks
Trial: 10088202
Drug: Metoprolol 95
RxNorm normalized name: metoprolol 95 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol 95 mg once a day for 4 weeks
Trial: 7529981
Drug: 2.5 mg/day
RxNorm normalized name: Androderm 2.5 MG/Day 24 HR Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg/day prednisolone
Trial: 7529981
Drug: 5.0 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5.0 mg/day prednisolone
Trial: 29141124
Drug: Overall Valbenazine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall Valbenazine treatment
Trial: 23374797
Drug: Fenoldopam (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenoldopam (0.1 μg/kg/min for 24 hours)
Trial: 19650803
Drug: Fascia iliaca
RxNorm normalized name: OCTINOXATE .012 mL in 6 mL / OCTISALATE .12 mL in 6 mL TOPICAL CREAM [RIMMEL LONDON MOISTURE RENEW LIPGLOSS - FUSCIA THERAPHY (345)]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fascia iliaca compartment block (FIC) with 30 ml of ropivacaine 3.75 mg/ml (112.5 mg) 20 min before spinal block
Trial: 19650803
Drug: Intravenous analgesia
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous analgesia with alfentanil (IVA) - bolus dose of 10 microg/kg, continuous infusion of 0.25 microg/kg/min starting 2 min before spinal block
Trial: 19650803
Drug: Intravenous analgesia
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous analgesia with alfentanil (IVA)
Trial: 15209007
Drug: Once weekly
RxNorm normalized name: Actonel 35 4-Week Once Weekly Dosepack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once weekly iron supplementation
Trial: 9971864
Drug: Restrictive transfusion
RxNorm normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restrictive transfusion strategy (transfusions if hemoglobin < 7.0 g/dL, maintained at 7.0 to 9.0 g/dL)
Trial: 9971864
Drug: Liberal transfusion
RxNorm normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liberal transfusion strategy (transfusions if hemoglobin < 10.0 g/dL, maintained at 10.0 to 12.0 g/dL)
Trial: 6932992
Drug: BCG and
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG and monthly chemotherapy
Trial: 6932992
Drug: Weekly irradiated
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly irradiated allogeneic blast cells
Trial: 31156155
Drug: Regular +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular + NPH Insulin
Trial: 31156155
Drug: Novo‐rapid +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novo‐rapid + Levemir Insulin
Trial: 28973074
Drug: SAbR plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAbR plus maintenance chemotherapy
Trial: 20223094
Drug: Glucosamine sulfate
RxNorm normalized name: Glucosamine Sulfate
DrugBank: Glucosamine (DB01296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glucosamine sulfate (1000 mg/day)
Trial: 10223757
Drug: Local anesthetic
RxNorm normalized name: Local anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anesthetic injection (1 to 2 ml of 2 percent lignocaine) during triple rubber band ligation
Trial: 10223757
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no local anesthetic injection) during triple rubber band ligation
Trial: 8847153
Drug: Brodimoprim 400
RxNorm normalized name: brodimoprim
DrugBank: Brodimoprim (DB13795)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brodimoprim 400 mg OD on the first day followed by 200 mg OD for 2 days
Trial: 8847153
Drug: Norfloxacin 400
RxNorm normalized name: norfloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norfloxacin 400 mg BID
Trial: 25733630
Drug: Hookworm treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hookworm treatment
Trial: 28534476
Drug: Conventional directly
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional directly observed therapy (DOT)
Trial: 26448482
Drug: Parental concerns
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parental concerns about treatment efficacy and side effects
Trial: 21359598
Drug: Ezetimibe monotherapy
RxNorm normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ezetimibe monotherapy 10 mg/day (EZT group)
Trial: 16860035
Drug: Enzyme replacement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzyme replacement therapy with human recombinant alpha‐L‐iduronidase
Trial: 10844053
Drug: Allopurinol (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol (300 mg daily) and nicotinamide (300 mg daily) for 3 months
Trial: 9093632
Drug: Chloroquine-Chlorpheniramine combination
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chloroquine-Chlorpheniramine combination
Trial: 3545785
Drug: Tetrabamate (three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetrabamate (three 300 mg tablets/day)
Trial: 21255807
Drug: α-lipoic acid
RxNorm normalized name: α-lipoic acid
DrugBank: Lipoic acid (DB00166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: α-lipoic acid 600 mg via intravenous infusion once a day for 3 weeks
Trial: 29931320
Drug: Estetrol (E4)
RxNorm normalized name: estetrol
DrugBank: Estetrol (DB12235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Estetrol (E4) 20 mg/d
Trial: 29931320
Drug: Estetrol (E4)
RxNorm normalized name: estetrol
DrugBank: Estetrol (DB12235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Estetrol (E4) 40 mg/d
Trial: 29931320
Drug: Estetrol (E4)
RxNorm normalized name: estetrol
DrugBank: Estetrol (DB12235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Estetrol (E4) 60 mg/d
Trial: 25081808
Drug: Daily weight
RxNorm normalized name: Thrifty White One Daily Weight Control Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily weight tracking
Trial: 25081808
Drug: Weekly weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly weight tracking
Trial: 18475028
Drug: Epidural injection
RxNorm normalized name: Sufentanil Citrate 50 ug in 1 mL EPIDURAL INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural injection of 1% ropivacaine and general anesthesia (epidural and general group, n=12)
Trial: 18475028
Drug: Epidural injection
RxNorm normalized name: Sufentanil Citrate 50 ug in 1 mL EPIDURAL INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural injection of saline and general anesthesia (general group, n=12)
Trial: 11326160
Drug: Cefotiam (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotiam (1 g) and Metronidazole (0.5 g) intravenously 30 min before surgery
Trial: 11326160
Drug: Cefoxitin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefoxitin (2 g) intravenously 30 min before surgery
Trial: 8781317
Drug: Steroids plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroids plus interferon
Trial: 1731672
Drug: Povidone-iodine solution
RxNorm normalized name: POVIDONE-IODINE 1 g in 100 mL TOPICAL LIQUID [Loris Povidone-Iodine Solution]
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Povidone-iodine solution (0.5%) irrigation
Trial: 26850805
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg of pomegranate extract daily for 30 days
Trial: 25628416
Drug: Indapamide SR/Amlodipine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indapamide SR/Amlodipine (Amlodipine 10 mg subgroup)
Trial: 25628416
Drug: Enalapril/Amlodipine (Amlodipine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril/Amlodipine (Amlodipine 10 mg subgroup)
Trial: 24124708
Drug: Low-dose rFVIIa
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose rFVIIa (20 µg/kg)
Trial: 21905967
Drug: Telmisartan 80
RxNorm normalized name: telmisartan 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan 80 mg plus Amlodipine 10 mg
Trial: 21905967
Drug: Telmisartan 40-80
RxNorm normalized name: telmisartan 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan 40-80 mg plus Amlodipine 10 mg
Trial: 17588688
Drug: L-arginine (7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine (7 gr/d)
Trial: 15454860
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of nicorandil (1.0 microg.kg(‐1).min(‐1))
Trial: 11207038
Drug: Group 1:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1: Cisplatin 20 mg/m(2) i.v. per day for 4 days, followed by Cy 2 g/m(2) i.v. on day 4; 12 partial responses (PR), 1 mixed response, 3 stable disease (SD).
Trial: 11207038
Drug: Group 2:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 2: Basic chemotherapy plus VP16 (50 mg/m(2) i.v. for 3 days) and Vincristine (1.5 mg/m(2) i.v. on days 1 and 6); 2 PR, 1 complete response (CR), and 2 very good partial responses (VGPR) in 5 patients treated at diagnosis.
Trial: 11207038
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (CO-TH) with 131-I-MIBG (200 mCi) administered on day 10 after chemotherapy; no extra-medullary toxicity observed, mild myelosuppression in patients treated at diagnosis.
Trial: 9398455
Drug: 0.125 mg
RxNorm normalized name: digoxin 0.125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.125 mg triazolam (oral)
Trial: 7991476
Drug: Thrombolytic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytic therapy (tissue plasminogen activator combined with intravenous heparin)
Trial: 7991476
Drug: Accelerated administration
RxNorm normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated administration of tissue plasminogen activator (Activase) combined with intravenous heparin
Trial: 3283460
Drug: HIGH arterial
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIGH arterial lactate concentrations (perioperative infusion of Ringer's lactate)
Trial: 22101205
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care plus cognitive behavioural therapy (CBT)
Trial: 8696720
Drug: Cisplatin and
RxNorm normalized name: A micelle drug formulation composed of cisplatin and mPEG-poly(l-Glu) diblock copolymer with 1,3-propanediyl linkagecisplatin is incorporated in polymeric micelles via polymer-metal complex formation with cis-geometry of PT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin and etoposide combination therapy
Trial: 2071959
Drug: CPR 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPR 0.5 g (0.5 g twice a day for 14 days)
Trial: 2071959
Drug: CPR 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPR 1.0 g (1.0 g twice a day for 14 days)
Trial: 2071959
Drug: CAZ (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAZ (1.0 g twice a day for 14 days)
Trial: 2071959
Drug: CPR 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPR 0.5 g (in patients with pneumonia)
Trial: 2071959
Drug: CPR 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPR 1.0 g (in patients with pneumonia)
Trial: 2071959
Drug: CPR 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPR 0.5 g (in patients with chronic respiratory tract infection)
Trial: 2071959
Drug: CPR 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPR 1.0 g (in patients with chronic respiratory tract infection)
Trial: 6140494
Drug: Concurrent internal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent internal sepsis
Trial: 31208475
Drug: Butter, cheese,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butter, cheese, whipped cream, sour cream
Trial: 19695922
Drug: Sodium glycididazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium glycididazole (700 mg/m² intravenous infusion 30 minutes before radiotherapy three times a week)
Trial: 1669033
Drug: CMI +
RxNorm normalized name: Clomipramine
DrugBank: Clomipramine (DB01242)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CMI + LT3 (clomipramine 150 mg/day + LT3 50 micrograms/day)
Trial: 1669033
Drug: CMI +
RxNorm normalized name: Clomipramine
DrugBank: Clomipramine (DB01242)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CMI + placebo (clomipramine 150 mg/day)
Trial: 6365008
Drug: Clotrimazole troches
RxNorm normalized name: clotrimazole
DrugBank: Clotrimazole (DB00257)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clotrimazole troches (10 mg) three times a day
Trial: 26762528
Drug: Varicella vaccine
RxNorm normalized name: Varicella vaccine
DrugBank: Varicella zoster vaccine (live/attenuated) (DB10318)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varicella vaccine without human serum albumin (HSA)
Trial: 26762528
Drug: Licensed varicella
RxNorm normalized name: VARICELLA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Licensed varicella vaccine containing HSA
Trial: 22332671
Drug: Control area
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control area (chemical keratolytic treatment)
Trial: 20382963
Drug: Treatment centre
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment centre
Trial: 22379913
Drug: Morphine and
RxNorm normalized name: morphine and antispasmodics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine and Lornoxicam
Trial: 16046230
Drug: Zinc oxide
RxNorm normalized name: Zinc Oxide
DrugBank: Zinc oxide (DB09321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zinc oxide suspension
Trial: 9510982
Drug: Josacine 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Josacine 500 mg tablets (2 tablets)
Trial: 9510982
Drug: Josamycin solution
RxNorm normalized name: josamycin
DrugBank: Josamycin (DB01321)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Josamycin solution (1 g drug, buffered at pH 4.0)
Trial: 7985598
Drug: Nadolol therapy
RxNorm normalized name: Nadolol
DrugBank: Nadolol (DB01203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nadolol therapy
Trial: 2686453
Drug: Triphasic oral
RxNorm normalized name: CeeNU, triphasic oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triphasic oral contraceptives
Trial: 30533392
Drug: On-table extubation
RxNorm normalized name: Table sugar
DrugBank: Sucrose (DB02772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: On-table extubation (OTE) group with sufentanil 0.15 µg/kg/h
Trial: 30533392
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with sufentanil 0.7-0.8 µg/kg/h
Trial: 20885970
Drug: Secnidazole (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secnidazole (2 g, once)
Trial: 20885970
Drug: Metronidazole (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole (500 mg, b.i.d for seven days)
Trial: 18978097
Drug: Diaphragm and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diaphragm and lubricant gel provision
Trial: 8871834
Drug: OH-chloroquine (OH-C)
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: OH-chloroquine (OH-C) 6 mg/kg/daily
Trial: 6144316
Drug: Pancuronium (loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pancuronium (loading dose 0.075 mg kg‐1, maintenance 0.015 mg kg‐1 every 42 min)
Trial: 6144316
Drug: Vecuronium (loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vecuronium (loading dose 0.075 mg kg‐1, maintenance 0.015 mg kg‐1 every 12 min)
Trial: 6144316
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of vecuronium (loading dose 0.075 mg kg‐1, continuous infusion 0.075 mg kg‐1 h‐1)
Trial: 25113425
Drug: Left nostril
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Left nostril (Group L; n = 95)
Trial: 18031501
Drug: Pimecrolimus cream
RxNorm normalized name: Pimecrolimus
DrugBank: Pimecrolimus (DB00337)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pimecrolimus cream and 1% hydrocortisone cream
Trial: 15990738
Drug: High-dose glucose-insulin-potassium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose glucose-insulin-potassium (GIK) infusion
Trial: 12469639
Drug: Intravesical immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical immunotherapy with imuron (6-week course) and maintenance therapy (3 weekly instillations each 3 months for the first year followed by once in 6 months)
Trial: 12469639
Drug: Single monthly
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Single monthly instillations
Trial: 12469639
Drug: Intravesical BCG-therapy
RxNorm normalized name: BCG, live, Tice strain
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical BCG-therapy
Trial: 7614099
Drug: Olsalazine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olsalazine 0.5 g daily
Trial: 7614099
Drug: Olsalazine 1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olsalazine 1.25 g daily
Trial: 7614099
Drug: Olsalazine 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olsalazine 2.0 g daily
Trial: 7614099
Drug: Sulphasalazine 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulphasalazine 2.0 g daily
Trial: 7614099
Drug: Olsalazine (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olsalazine (all doses)
Trial: 2615532
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of nystatin (NYS), pipemidic acid (PPA), and colistin sodium methanesulfonate (CLM)
Trial: 21320227
Drug: Prescription group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescription group (standard prescription)
Trial: 19961726
Drug: Admission blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Admission blood glucose < 6.1 mmol/L
Trial: 19961726
Drug: Admission blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Admission blood glucose 6.1 to 7.7 mmol/L